Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2.

The PTEN and TSC2 tumor suppressors inhibit mammalian target of rapamycin (mTOR) signaling and are defective in distinct hamartoma syndromes. Using mouse genetics, we find that Pten and Tsc2 act synergistically to suppress the severity of a subset of tumors specific to loss of each of these genes. Interestingly, we find that the slow-growing tumors specific to Tsc2+/- mice exhibit defects in signaling downstream of Akt. However, Pten haploinsufficiency restores Akt signaling in these tumors and dramatically enhances their severity. This study demonstrates that attenuation of the PI3K-Akt pathway in tumors lacking TSC2 contributes to their benign nature.

[1]  L. Aicher,et al.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. , 2002, Cancer research.

[2]  H. Onda,et al.  Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. , 1999, The Journal of clinical investigation.

[3]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[5]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Hongbing Zhang,et al.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. , 2002, Human molecular genetics.

[7]  P. Pandolfi,et al.  Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. , 2005, Genes & development.

[8]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[9]  T. Noda,et al.  Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. , 1999, Cancer research.

[10]  B. Manning.  Balancing Akt with S6K , 2004, The Journal of cell biology.

[11]  D. Kwiatkowski,et al.  Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. , 2005, Cancer research.

[12]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[13]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[14]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[15]  C. Thompson,et al.  Akt Activation Promotes Degradation of Tuberin and FOXO3a via the Proteasome* , 2003, The Journal of Biological Chemistry.

[16]  Hongbing Zhang,et al.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. , 2003, The Journal of clinical investigation.

[17]  D. Kwiatkowski,et al.  Tuberous Sclerosis: from Tubers to mTOR , 2003, Annals of human genetics.

[18]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[19]  D. Kwiatkowski,et al.  Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation , 2002, The Journal of Biological Chemistry.

[20]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[21]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[22]  P. Pandolfi,et al.  Impaired Fas response and autoimmunity in Pten+/- mice. , 1999, Science.

[23]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[24]  Eric C. Griffith,et al.  The Many Forks in FOXO's Road , 2003, Science's STKE.

[25]  E. Henske.  Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond , 2005, Pediatric Nephrology.

[26]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[27]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[29]  P. Vogt,et al.  A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Hongbing Zhang,et al.  Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models , 2005 .

[31]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[32]  Hongbing Zhang,et al.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma , 2003, The Lancet.

[33]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[35]  P. Pandolfi,et al.  PTEN in Neural Precursor Cells: Regulation of Migration, Apoptosis, and Proliferation , 2002, Molecular and Cellular Neuroscience.

[36]  G. Thomas,et al.  Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. , 2002, Genes & development.

[37]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[38]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.